- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04181684
LITT Followed by Hypofractionated RT for Recurrent Gliomas (GCCC 19140)
May 2, 2023 updated by: Department of Radiation Oncology, University of Maryland, Baltimore
Pilot Study of Laser Interstitial Thermal Therapy Followed By Hypofractionated Radiation Therapy for Treatment of Recurrent Gliomas.
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Radiation therapy is preferably used as an adjunct to surgery for patients with a newly diagnosed or recurrent glioblastoma.
LITT offers an alternative to surgical resection, and due to its minimally invasive nature, does not delay initiating radiation therapy.
Another advantage of LITT prior to radiation therapy is the ability to obtain a tissue diagnosis of recurrent tumor prior to initiating radiation therapy.
Study Type
Interventional
Enrollment (Anticipated)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Megan A Camara, RN
- Phone Number: 410-369-5355
- Email: megan.camara@umm.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland Greenebaum Cancer Center
-
Contact:
- Megan Camara
- Phone Number: 410-369-5226
-
Bel Air, Maryland, United States, 21014
- Recruiting
- UCH Kaufman Cancer Center
-
Columbia, Maryland, United States, 21044
- Recruiting
- Central Maryland Radiation Oncology
-
Glen Burnie, Maryland, United States, 21061
- Recruiting
- Baltimore Washington Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Patients with history of a WHO Grade II-IV glioma with radiographic evidence of recurrent or progressive tumor
- Patient must have received prior radiation therapy for initial treatment of glioma
- Patients with any number of recurrences are allowed as long as the patient has not undergone re-irradiation
- Brain MRI with contrast demonstrates an enhancing tumor ≤ 6 cm in largest diameter within 60 days prior to registration
- History and physical including neurological exam within 30 days prior to registration
- Karnofsky performance status ≥ 60% within 30 days prior to registration
- Age ≥ 22 years old
Minimum interval since completion of prior radiation treatment is 8 weeks
- Patients will only receive re-irradiation if pathology from LITT is consistent with recurrent tumor
- Patients must have signed an approved informed consent
- Patients with the potential for pregnancy or impregnating their partner must agree to practice effective contraceptive methods to avoid conception while on study and for 6 months after study completion.
- Female patients of child-bearing potential must have a negative pregnancy test within 28 days prior to study registration.
Exclusion Criteria:
- Patients that are not surgical candidates for stereotactic biopsy or laser ablation
Patients with impaired cardiac function or clinically significant cardiac diseases, including any of the following:
- History or presence of serious uncontrolled ventricular or significant arrhythmias.
- Any of the following within 6 months prior to registration: myocardial infarction, severe/unstable angina, coronary artery bypass graft, congestive heart failure, cerebrovascular accident, transient ischemic attack , pulmonary embolism
- Infratentorial tumor or evidence of leptomeningeal spread
- Inability to undergo a MRI
- Pregnant or breast-feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: LITT with Hypofractionated radiation therapy
Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 35Gy/10 fractions.
|
This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
Other Names:
Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week).
Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 2 years
|
To complete protocol treatment without undue treatment-related acute toxicity in recurrent or progressive glioma subjects undergoing LITT followed by hypofractionated radiation therapy.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival at 6 months
Time Frame: 2 Years
|
To describe progression-free survival rate in subjects with recurrent or progressive gliomas treated with Laser Interstitial Thermal Therapy
|
2 Years
|
Median progression-free survival
Time Frame: 2 Years
|
To describe median progression-free survival rate in subjects with recurrent or progressive gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.
|
2 Years
|
Median overall survival
Time Frame: 2 years
|
To describe median progression-free survival rate in subjects with recurrent or progressive gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.
|
2 years
|
1-year overall survival
Time Frame: 2 years
|
To describe 1 year overall survival rate in subjects with recurrent or progressive gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.
|
2 years
|
Overall response rate
Time Frame: 2 years
|
To describe overall response survival rate in subjects with recurrent or progressive gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.
|
2 years
|
Quality of Life before, during, and after treatment
Time Frame: 2 years
|
Patient reported quality of life impact from undergoing LITT followed by hypofractionated radiation therapy using the M.D. Anderson Symptom Inventory- Brain Tumor (MDASI-BT) questionnaire.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2020
Primary Completion (Anticipated)
December 1, 2024
Study Completion (Anticipated)
December 1, 2026
Study Registration Dates
First Submitted
November 24, 2019
First Submitted That Met QC Criteria
November 26, 2019
First Posted (Actual)
November 29, 2019
Study Record Updates
Last Update Posted (Estimate)
May 4, 2023
Last Update Submitted That Met QC Criteria
May 2, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Glioblastoma
- Glioma
- Brain Neoplasms
Other Study ID Numbers
- HP-00088569
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on Procedure: LITT
-
Beijing Tiantan HospitalRecruiting
-
Children's Hospitals and Clinics of MinnesotaCompletedBrain TumorUnited States
-
Radboud University Medical CenterUMC Utrecht; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsActive, not recruitingPrimary GlioblastomaNetherlands
-
M.D. Anderson Cancer CenterBioTex, Inc.Terminated
-
Rutgers, The State University of New JerseyRutgers Cancer Institute of New JerseyTerminated
-
University of Maryland, BaltimoreKeep Punching FoundationRecruitingGlioma | Glioblastoma | Brain TumorUnited States
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
Icahn School of Medicine at Mount SinaiCompletedGlioblastoma | GBMUnited States
-
Beijing Tiantan HospitalActive, not recruitingRecurrent GlioblastomaChina
-
University of FloridaMonteris MedicalTerminatedMelanoma | Primary Mediastinal Large B-Cell Lymphoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Cancer | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Brain Metastases, Adult | Renal Cell... and other conditionsUnited States